Fellow Eye Anti-VEGF 'Crunch' Effect in Retinopathy of Prematurity.
Ophthalmic Surg Lasers Imaging Retina
; 49(9): e102-e104, 2018 09 01.
Article
em En
| MEDLINE
| ID: mdl-30222828
ABSTRACT
BACKGROUND AND OBJECTIVE:
Anti-vascular endothelial growth factor (VEGF) therapy is increasing in popularity for treatment of retinopathy of prematurity (ROP). Despite many technical benefits, issues remain prompting further investigation. PATIENTS ANDMETHODS:
Retrospective case report and literature review.RESULTS:
A 42-week-old postmenstrual age female with gestational age of 28 weeks and birth weight of 990 g presented with prominent progression of peripapillary purely tractional atypical stage 4A ROP in both eyes following intravitreal bevacizumab therapy in the right eye only.CONCLUSION:
The authors present the first reported case, to their knowledge, of a "crunch" phenomenon tractional retinal detachment from fellow eye administration of bevacizumab. [Ophthalmic Surg Lasers Imaging Retina. 2018;49e102-e104.].
Texto completo:
1
Coleções:
01-internacional
Base de dados:
MEDLINE
Assunto principal:
Retinopatia da Prematuridade
/
Descolamento Retiniano
/
Inibidores da Angiogênese
/
Bevacizumab
Tipo de estudo:
Observational_studies
Limite:
Female
/
Humans
/
Infant
Idioma:
En
Revista:
Ophthalmic Surg Lasers Imaging Retina
Ano de publicação:
2018
Tipo de documento:
Article